GT Biopharma Announces Completion of First Four Patients in FDA Phase 2 Trial of Cancer Drug OXS-1550 October 10, 2017
GT Biopharma, Inc. Announces Corporate Update Conference Call with CEO Dr. Kathleen Clarence-Smith, CMO Dr. Raymond Urbanski and Chairman Anthony Cataldo September 27, 2017
GT Biopharma Announces Development Plan For Non-Opioid Neuropathic Pain Treatment "PainBrake" September 11, 2017
GT Biopharma Hires Former Pfizer CMO/Vice President and Senior Director of Oncology Research as Chief Medical Officer September 7, 2017
GT Biopharma, Inc, Announces Closing of OXIS International - Georgetown Translational Pharmaceuticals Merger September 5, 2017
GT Biopharma, Inc. Announces Reverse Stock Spilt As Part of Oxis-Georgetown Planned Merger August 21, 2017
GT Biopharma, Inc. (Oxis) Announces Corporate Update Conference Call With Incoming CEO Dr. Kathleen Clarence-Smith and Chairman Anthony Cataldo August 7, 2017
GT Biopharma (OXIS) Announces Enrollment of Fourth Patient in FDA Phase 2 Trial of Cancer Drug OXS-1550 August 2, 2017
